Evidence map›Paper›PMID 42558296›Full record

ArticleChina CDC weekly2026

Changes in RPV Resistance-Related Mutations Among Antiretroviral Therapy-Naïve HIV-1-Positive Individuals - China, 2004-2023.

Xiang Li, Xiu Liu, Peixian Xin, Dong Wang, Jingjing Hao, Chang Song, Jing Hu, Yi Feng, Yuhua Ruan, Hui Xing and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiang LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Xiu LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Peixian XinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Dong WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Jingjing HaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Chang SongNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Jing HuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Yi FengNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Yuhua RuanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Hui XingNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Lingjie LiaoNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rilpivirine (RPV) is currently included in first-line antiretroviral therapy (ART) regimens in China. However, the baseline RPV resistance remains unclear, especially among different HIV-1 subtypes in China. Methods: HIV-1 Results: In total, 64,429 HIV-1 Conclusions: Polymorphic RAMs and NNRTI cross-resistance mutations together account for the increased RPV resistance in China. Additional phenotypic data and clinical research are needed to verify the efficacy of RPV-based ART in patients infected with subtypes CRF65_cpx, CRF55_01B, and CRF08_BC.

Indexed as

Antiretroviral therapy (ART)Drug resistanceHIV-1Resistance mutationsRilpivirine (RPV)

Identifiers

PMID42558296
PMCPMC13437196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.